LPCN 1021
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypogonadism, Male
Conditions
Hypogonadism, Male
Trial Timeline
Jan 1, 2017 → Jul 1, 2017
NCT ID
NCT03242408About LPCN 1021
LPCN 1021 is a phase 3 stage product being developed by Lipocine for Hypogonadism, Male. The current trial status is completed. This product is registered under clinical trial identifier NCT03242408. Target conditions include Hypogonadism, Male.
What happened to similar drugs?
6 of 18 similar drugs in Hypogonadism, Male were approved
Approved (6) Terminated (3) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03868059 | Phase 3 | Completed |
| NCT03242408 | Phase 3 | Completed |
| NCT03242590 | Phase 3 | Completed |
Competing Products
20 competing products in Hypogonadism, Male